CART deficiency increases body weight but does not alter bone strength

S.M. Bartell², C.M. Isales¹, C.A. Baile², M.J. Kuhar³, M.W. Hamrick¹

¹Department of Cellular Biology & Anatomy, Department of Orthopaedic Surgery & Institute of Molecular Medicine & Genetics, Medical College of Georgia, Augusta, GA, USA; ²Animal & Dairy Science, University of Georgia, Athens, GA, USA; ³Division of Neuroscience, Yerkes National Primate Research Center of Emory University, Atlanta, GA, USA

Abstract

The regulation of bone metabolism mediated by leptin is a complex process that is not clearly understood. Recent studies suggest that CART (cocaine-amphetamine related transcript) is a significant neuronal co-factor when combined with leptin. CART deficiency is thought to result in low trabecular bone mass, but since leptin exerts contrasting effects on trabecular and cortical bone it is possible that cortical bone may not respond to the absence of CART signaling in the same manner as trabecular bone. We tested the hypothesis that CART deficiency decreases cortical bone mass, density, and strength by examining femora of adult wild-type mice (CART+/−) and CART-deficient mice (CART−). DEXA densitometry (PIXImus system) was used to measure whole-bone mineral content (BMC) and mineral density (BMD) from right femora, and pQCT used to calculate densitometric and geometric parameters from the femur midshaft. Femora were also tested in three-point bending, and sections of the tibia analyzed histologically to determine bone marrow adipocyte density (N.At./M.Ar) and endocortical osteoclast number (N.Oc/B.Pm). The control mice weighed less than the mice lacking CART (P<0.001), but mechanical testing data showed no differences (p>0.05) in ultimate force, energy to fracture, stiffness, or intrinsic properties such as ultimate stress, ultimate strain, or modulus. CART-deficient mice did not differ from normal controls in whole-femur BMC (p=0.09), BMD (p=0.19), midshaft cortical bone thickness (p=0.67), midshaft cortical bone area (p=0.59) or N.Oc/B.Pm (p=0.94), although CART deficiency was associated with a three-fold increase in bone marrow adipocyte density (p<0.001). Our data suggest that while the central, neuroendocrine regulation of bone mass via CART signaling may have effects on trabecular mass, absence of CART expression does not significantly alter cortical bone geometry, density, or strength.

Keywords: Leptin, Adipocyte, Bone Mass, Cortical Bone, Body Weight

Introduction

The regulation of bone metabolism mediated by leptin is a complex process that is not clearly understood. The findings of increased trabecular bone formation and high bone mass within the proximal tibia and lumbar vertebrae of ob/ob mouse¹, with similar observations in the db/db mouse, led to the conclusion that leptin signals through its known receptor to control bone mass. Intracerebroventricular (ICV) infusion of leptin into the third ventricle resulted in bone loss in both ob/ob and wild-type mice, suggesting that leptin acts via the central nervous system to inhibit bone formation⁴. The absence of detectable leptin in the serum of ICV-administered ob/ob mice also supports a central mode of leptin action. A parabiosis model, in which only one ob/ob mouse of a parabiosed pair received ICV leptin, was used to confirm the key role hypothalamic leptin plays in regulating bone formation⁵. Correction of the ob/ob skeletal phenotype by loss of bone mass was only achieved in the leptin recipient and not in the contralateral mouse², indicating that similar to its control of energy homeostasis by central mediation, the action of leptin on bone can be regulated through a similar hypothalamic relay.

There are, however, contradictory findings when assessing leptin treatment on bone mass in rodents. Some studies have
described ob/ob mice (leptin-deficient) that were adminis-
tered leptin as having a "high bone mass"\textsuperscript{a,3,4}, while Steppan
et al.\textsuperscript{3} observed that leptin-deficient mice had lower bone
mass than normal mice. One explanation of the discrepan-
cies of results reported may be due to mode of leptin admin-
istration. Peripheral (SQ) administration of leptin could
increase bone growth and indices of bone formation\textsuperscript{a-7}
whereas central (ICV) infusion of leptin might lead to bone
loss\textsuperscript{1}, revealing that leptin can regulate bone mass through
alternative pathways: one involving a direct stimulatory
effect on bone growth when administered peripherally and
another that is indirect, involving a hypothalamic relay that
suppresses bone formation when administered centrally\textsuperscript{a}.
However, in the recent study by Iwaniec et al.\textsuperscript{9} in which
ob/ob mice were injected in the hypothalamus with a recom-
binant adenovirus expressing leptin, femoral bone mass and
length increased while cancellous bone volume in both the
femur and spine declined. Together these studies indicate
that, regardless of whether leptin is administered centrally or
peripherally, leptin decreases cancellous bone volume while
at the same time increasing cortical bone mass.

Because of the complexity of understanding leptin's role
in the regulation of bone, several recent studies have been
conducted with neuronal co-factors such as beta-adrenergic
receptors (\(\beta\)-AR), neuropeptide Y (NPY), and CART that
are regulated by leptin expression in the hypothalamus.
Sympathetic tone is reduced in leptin-deficient mice\textsuperscript{10}, and
studies involving \(\beta\)-AR agonists and antagonists demon-
strate that the central actions of leptin are mediated via the
sympathetic nervous system (SNS). Resembling the sympa-
thetic hypotonic ob/ob mouse are mice lacking both \(\beta\)1 and
\(\beta\)2-adrenergic receptors, which demonstrate increased tra-
becular number but decreased cortical bone\textsuperscript{11}.
Administration of \(\beta\)-AR antagonists increased bone mass in
vertebrae and long bones of ob/ob and wild-type mice\textsuperscript{2}.
Conversely, administration of \(\beta\)-AR agonists restored sympa-
thetic activity in ob/ob mice, and decreased bone mass in both the ob/ob and wild-type mice without affecting body
weight\textsuperscript{12}, demonstrating that the modulation of SNS activity
can affect bone remodeling. It should, however, be noted
here that neonatal sympathectomized mice has no demonstrable
effects on cortical bone\textsuperscript{13}. Another neuronal co-factor that
interacts with leptin is NPY, a target of leptin signaling with-
in the hypothalamus that regulates energy balance, modulat-
ing feeding behavior, and bone metabolism through at least
five receptors (Y1, Y2, Y4, Y5, and Y6). The finding that
trabecular and cortical bone formation and volume are
increased in the absence of NPY signaling in mice\textsuperscript{14-18} strongly
supports a role for NPY receptor signaling in the regula-
tion of bone formation. Thus, Y2 receptor signaling along
with leptin regulates bone formation via a hypothalamic relay in both trabecular and cortical bone.

Through recent studies, CART (cocaine-amphetamine
related transcript) has been revealed to be an important neu-
ropeptide regulated by leptin. CART is expressed at high
levels in the mouse hypothalamus\textsuperscript{19}, and CART expression is
upregulated with injection of psychostimulants, suggesting
that CART may antagonize the effects of these drugs\textsuperscript{20}.
CART has so far been detected in the posterior pituitary, the
adrenal medulla, and endocrine cells in the gut\textsuperscript{19}. CART
peptide also decreases food intake after intracerebroventric-
ular injection in rats, implicating CART as a potential regu-
lator of feeding, satiety, and body weight\textsuperscript{21}. CART expres-
sion in the hypothalamus is also upregulated by leptin\textsuperscript{22}.
Recently, it was found that CART-deficient mice have low
bone mass in their spine, suggesting that the effects of leptin
on bone mass in the axial skeleton may be mediated at least
in part by CART signaling, acting through a central, neuroendocrine signaling pathway\textsuperscript{12}. It has been proposed that
while leptin may increase bone resorption by stimulating
RANK-ligand (RANKL) expression in osteoblasts, leptin
can also inhibit osteoclast activity by increasing CART
expression, which decreases RANKL expression by osteoblasts\textsuperscript{12}.

The effects of CART deficiency on bone mass have so far
only been examined in trabecular bone of the vertebrae. As
noted above, CART deficiency is thought to result in low tra-
becular bone mass, but since leptin exerts different effects on
cortical and trabecular bone it is possible that cortical bone
may not respond to the absence of CART signaling in the
same manner as trabecular bone. Periosteum is richly innerv-
ated and is supplied by a dense network of sensory and sympa-
thetic fibers\textsuperscript{23}, but it is unknown how altering CART
affects periosteal and endosteal apposition during growth
and aging. This is an important consideration, because periosteal expansion and cortical bone cross-sectional geometry are key determinants of hip fracture risk\textsuperscript{24}. We tested
the hypothesis that CART deficiency decreases cortical bone
mass, density, and strength by examining femora of adult
CART-deficient mice. It was predicted that bone mineral
content, density, femoral fracture strength, and toughness
would be lower in CART-deficient mice than normal mice,
due to an increase in bone resorption. The long-term objec-
tive of this study is to better understand the role of central,
neuroendocrine signaling pathways in regulating bone
metabolism and bone strength.

Methods

Sample

Male mice, 6 months of age were used for this study. The
sample size includes 18 CART-deficient (CART\textsuperscript{-/-}) mice on
a C57BL6 background and 18 wild-type (CART\textsuperscript{+/-}) C57BL6
mice\textsuperscript{21}. Mice were obtained from the CART\textsuperscript{-/-}
breeding colony at Eli Lilly and shipped live to MJK at the Yerkes
Primate Facility. Mice were euthanized by CO\textsubscript{2}, weighed,
and the left hindlimb dissected free and stored at -20\textdegree C for
mechanical testing. The right hindlimb was fixed for 24 hours
in neutral buffered formalin and then stored in 70\% ETOH
prior to densitometry.
Densitometry

Dual-energy X-ray absorptiometry (DEXA) densitometry (PIXImus system) was used to measure whole-bone mineral content (BMC) and mineral density (BMD) from right femora. pQCT densitometry, a reliable approach for measuring trabecular and cortical bone area, mineral content, mineral density, and cross-sectional geometry in small rodent bones, was then used to calculate BMC, BMD, cortical area, cortical thickness, periosteal circumference, and endosteal circumference from a single cross-section, 1 mm thick, at the femur midshaft. Sections were scanned at 4 mm/sec with a voxel size of 0.070 mm and a threshold value of 524.0 mg/cm³ using a Norland Stratec XCT-Research peripheral quantitative computed tomography (pQCT) machine housed in the Department of Biochemistry and Molecular Pathology at the Northeast Ohio Universities College of Medicine (NEOUCOM).

Mechanical testing

Left femora were dissected free, thawed in cold water at room temperature for 1 hour, and then prepared for mechanical testing in 3-point anteroposterior bending using a Vitrodyne V1000 Materials Testing system (Liveco Inc., Burlington, VT, USA). Femora were mounted on stainless steel fixtures spaced 5 mm apart and 2.5 mm either side of center. Testing was linear displacement control with a displacement rate of 0.10 mm/sec using a Transducer Techniques 5 kg load cell. Femora were loaded to failure with data points recorded every .01 sec. Structural, or intrinsic properties, such as ultimate force (Fₚ; height of curve), stiffness (S; slope of curve), ultimate displacement (dₚ; width of curve), and energy to fracture (U; area under curve) were calculated from load-displacement curves. The cross-sectional moment of inertia (CSMI) was calculated for each specimen using the external diameter and cortical thickness, measured from histological sections (described below). CSMI = π*(2R²-I)²/8, where 2R equals the external diameter and t equals the cortical thickness. Ultimate stress (σₒ) was calculated as Fₒ/Lb/8I, ultimate strain (εₒ) as dₒ/6b/L², and Young’s modulus (E) as S*(L²/48I) where L equals length of the test specimen (5 mm), b equals anteroposterior diameter of the specimen, and I is the cross-sectional moment of inertia (CSMI).

Histology and histomorphometry

The right tibia and L4 vertebra were decalcified in 4% EDTA for approximately 1 week and then embedded in paraffin following standard procedures. Transverse sections were cut at 5 μm and stained with hematoxylin and eosin (H&E to yield tibial sections used for measuring total section area (T.Ar), marrow area (M.Ar), cortical area (Ct.Ar), cortical thickness (Ct.Wi), and adipocyte density (N.At./M.Ar). Adipocytes were counted over a 0.50 mm² area. Trabecular volume and total bone volume were measured from H&E stained sections of the vertebrae to determine relative bone volume fraction (BV/TV). Sections from the tibia and L4 vertebra were also stained for tartrate-resistant acid phosphatase (TRAP) as a marker of active osteoclasts. Osteoclasts were counted on the tibial endosteal surface and expressed as a number of osteoclasts per bone perimeter (N.Oc/B.Pm).

Statistical analysis

Single-factor ANOVA with genotype as the factor was used to test for between-group differences in the densitometric and biomechanical variables examined, and ANCOVA was used to adjust variables for differences in body weight employing body mass as a covariate. Significance is established at p<0.05.

Results

The wild-type mice weighed significantly less than the CART⁻/⁻ mice (p<0.001), but CART⁻/⁻ mice did not differ from wild-type mice in whole-femur BMC (p=0.09), BMD (p=0.19), midshaft cortical bone thickness (p=0.67), or midshaft cortical bone area (p=0.59; Table 1, Figure 1a). ANCOVA results indicate that femur BMC is lower in CART⁻/⁻ than in wild-type mice when the data are adjusted for body weight (Table 1), however no other parameters differ between groups in ANCOVA analyses (Tables 1, 2). Mechanical testing data (Table 2) showed no differences (p>0.05) in ultimate force, energy to fracture, stiffness, or intrinsic properties such as ultimate stress, ultimate strain, or modulus. Histological sections stained for osteoclast activity showed few osteoclasts along the endosteal surface of the proximal tibia in wild-type mice and CART⁻/⁻ mice (Figure 1c), and no significant differences in osteoclasts per bone perimeter (N.Oc/B.Pm) between the groups (p=0.94; Figure 2a). H&E staining for adipocyte number show more adipocytes in the bone marrow of the CART⁻/⁻ mice (Figure 1b) and greater bone marrow adipocyte density (N.At/M.Ar) than the wild-type mice (p<0.001; Figure 2b). Data from the L4 vertebrae demonstrate that bone volume fraction and osteoclasts per bone perimeter are similar between the two groups of mice (Figure 3).

Discussion

Evidence from the leptin-deficient ob/ob mouse, and from mice lacking beta-adrenergic receptors, suggest that cortical and trabecular bone are regulated through different leptin- mediated pathways. Leptin suppresses NPY and stimulates beta-adrenergic receptors, both of which increase cortical bone formation, whereas activation of the beta-adrenergic pathway appears to inhibit trabecular bone formation and may increase trabecular resorption. Likewise, Elefteriou et
Table 1. Body mass and densitometric properties of the femur from wild-type (CART\textsuperscript{+/+}) and CART-deficient (CART\textsuperscript{-/-}) mice.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CART\textsuperscript{+/+} (n=18)</th>
<th>CART\textsuperscript{-/-} (n=18)</th>
<th>P-value (ANOVA)</th>
<th>P-value (ANCOVA)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MEAN</td>
<td>SD</td>
<td>MEAN</td>
<td>SD</td>
</tr>
<tr>
<td>Body mass (g)</td>
<td>31.3</td>
<td>3.0</td>
<td>35.5</td>
<td>2.6</td>
</tr>
<tr>
<td>Femur BMC (g)</td>
<td>0.023</td>
<td>0.004</td>
<td>0.021</td>
<td>0.001</td>
</tr>
<tr>
<td>Femur BMD (g/cm\textsuperscript{2})</td>
<td>0.051</td>
<td>0.005</td>
<td>0.050</td>
<td>0.002</td>
</tr>
<tr>
<td>Midshaft BMC (mg/mm)</td>
<td>0.73</td>
<td>0.16</td>
<td>0.72</td>
<td>0.14</td>
</tr>
<tr>
<td>Midshaft BMD (mg/cm\textsuperscript{3})</td>
<td>515.9</td>
<td>57.5</td>
<td>519.6</td>
<td>50.3</td>
</tr>
<tr>
<td>Cortical area (mm\textsuperscript{2})</td>
<td>0.88</td>
<td>0.10</td>
<td>0.86</td>
<td>0.04</td>
</tr>
<tr>
<td>Cortical thickness (mm)</td>
<td>0.19</td>
<td>0.05</td>
<td>0.19</td>
<td>0.02</td>
</tr>
<tr>
<td>Periosteal circumference (mm)</td>
<td>4.4</td>
<td>0.40</td>
<td>4.3</td>
<td>0.40</td>
</tr>
<tr>
<td>Endosteal circumference (mm)</td>
<td>3.0</td>
<td>0.80</td>
<td>3.1</td>
<td>0.21</td>
</tr>
</tbody>
</table>

*ANCOVA results refer to analyses using body mass as a covariate.

Figure 1. pQCT cross-sections of the femur (a), H&E stained tibial cross-sections (b), and TRAP stained tibial sections (c) from CART\textsuperscript{-/-} (left column) and CART\textsuperscript{+/+} (right column) mice. Note that the two strains of mice do not differ in cortical bone structure (top), bone marrow adipocyte number (middle), and osteoclast number (bottom).
<table>
<thead>
<tr>
<th>Parameter</th>
<th>CART&lt;sup&gt;++&lt;/sup&gt; (n=18)</th>
<th>CART&lt;sup&gt;-/-&lt;/sup&gt; (n=18)</th>
<th>p-value (ANOVA)</th>
<th>p-value (ANCOVA)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fu (N)</td>
<td>21.7 ± 2.8</td>
<td>21.3 ± 1.6</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Du (mm)</td>
<td>0.61 ± 0.21</td>
<td>0.51 ± 0.16</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>S (N/mm)</td>
<td>65.5 ± 12.9</td>
<td>67.9 ± 13.1</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>U (N-mm)</td>
<td>8.1 ± 2.3</td>
<td>7.1 ± 1.9</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>CSMI (mm&lt;sup&gt;4&lt;/sup&gt;)</td>
<td>0.083 ± 0.031</td>
<td>0.080 ± 0.01</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Ultimate stress (σ&lt;sub&gt;U&lt;/sub&gt;; N/mm&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>198.4 ± 30.9</td>
<td>204.1 ± 29.9</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Ultimate strain (ε&lt;sub&gt;U&lt;/sub&gt;)</td>
<td>0.17 ± 0.06</td>
<td>0.15 ± 0.05</td>
<td>ns</td>
<td>ns</td>
</tr>
<tr>
<td>Young's modulus (E; N/mm&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>14.2 ± 6.2</td>
<td>14.1 ± 3.4</td>
<td>ns</td>
<td>ns</td>
</tr>
</tbody>
</table>

*ANCOVA results refer to analyses using body mass as a covariate.

**Table 2.** Mechanical testing data of the femur from wild-type (CART<sup>++</sup>) and CART-deficient (CART<sup>-/-</sup>) mice.

**Figure 2.** Histograms showing tibial osteoclast per surface (a) and bone marrow adipocyte number (b).
al.\textsuperscript{12} found that the absence of CART leads to a decrease in trabecular bone volume because of an isolated increase in osteoclast activity following RANKL overexpression by osteoblasts. Our findings indicate that the deletion of CART yields no detectable increase in the number of endocortical osteoclasts or vertebral osteoclasts, and no decrease in cortical thickness, cortical area, or trabecular bone volume fraction. Thus, leptin signaling appears to be anabolic for cortical bone, and hence the body fat-bone axis links cortical bone with weight support\textsuperscript{31}. It is unclear why our results for trabecular bone volume fraction and osteoclast number differ from those of Elefteriou et al.\textsuperscript{12}, since the mice were of the same age, although the animals in our study were male and the mice in their study were female. It is also possible that feeding behavior and body composition (and hence bone metabolism) may differ between knockout mice from different colonies. For example, food intake and fat pad weights were slightly lower in CART\textsuperscript{-/-} mice compared to wild-type mice in the study by Elefteriou et al.\textsuperscript{12}, whereas fat pad weights were similar and food intake increased in the CART\textsuperscript{-/-} studied by Zhang et al.\textsuperscript{32}.

Leptin is a factor that plays a major role in regulating appetite, energy expenditure, and body weight, and leptin treatment can induce apoptosis of fat cells (adipocytes) in peripheral fat pads as well as in bone marrow\textsuperscript{33-35}. Leptin can also act directly on bone marrow cells to enhance their differentiation to osteoblasts and inhibit their differentiation to adipocytes\textsuperscript{36}. Age plays a role in adipocyte accumulation, both in bone marrow and in peripheral fat depots. Marrow tissue in the limb bones is known to accumulate adipocytes with age, and this may contribute directly to bone loss and increased risk of fracture\textsuperscript{37,38}. The increase in bone marrow adipocyte density observed among the CART-deficient mice in this study suggests that CART may mediate leptin’s effect on adipogenesis in bone and lipid mobilization. This is further indicated by the fact that central (icv) infusions of CART peptide reduce fat pad weights in rodents\textsuperscript{19}; however, it should be noted that the increase in marrow adipogenesis observed among the CART knockout mice is much less than that observed among leptin-deficient ob/ob mice. For example, we found that the adipocyte density in the CART\textsuperscript{-/-} mice was approximately 14 adipocytes/mm sq, whereas ob/ob mice were shown to have an adipocyte density of approximately 47 adipocytes/mm sq\textsuperscript{32}.

Although CART may play a role in mediating leptin’s effects on bone marrow adipogenesis and adipocyte apoptosis, it does not appear to be involved in linking body weight with bone mass, especially cortical bone thickness and area.
CART-deficient mice weigh significantly more than wild-type mice, but show no differences in femur BMD, periosteal circumference, area moment of inertia, or strength and toughness with wild-type mice. Our data therefore suggest that while the central, neuroendocrine regulation of bone mass via CART signaling may have effects on trabecular mass, absence of CART expression does not significantly alter cortical bone geometry, density, or strength. While central leptin signaling and hypothalamic CART expression are known to regulate body weight, food intake, and satiety, it is likely that the beta-adrenergic and NPY pathways play a greater role in mediating the fat-bone axis downstream of leptin.

Acknowledgements

Supported by the Georgia Research Alliance (GRA) Eminent Scholar endowment (CAB), a GRA Challenge Grant (CAB & MJK), and the National Institutes of Health (DA 00418 to MJK). We are grateful to H. Hsiung and M. Asnicar at Eli Lilly & Co for the CART knockout mice, and M. Moffett at Yerkes for assistance with the animals.

References

26. Ferretti JL. Perspectives of pQCT technology associated to biomechanical studies in skeletal research employing rat models. Bone 1995;17(Suppl.):353S-64S.
27. Gasser JA. Assessing bone quantity by pQCT. Bone 1995;17(Suppl.):145S-54S.